This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Clinical Trials in IBD.

A Review of the Critical Role of Imaging in Primary Liver Malignancy

Why Gene Therapy for Hemophilia?

Treatment Algorithms in Melanoma: Past, Present, and Future

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Progression After Cancer Immunotherapy in Advanced NSCLC

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.

The Tumor Microenvironment

Updates in Management of Atopic Dermatitis From Real Patient Cases

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Induction Chemotherapy for Patients With High-Risk or Secondary AML

PARP Inhibitors and Cancer: What Do You Need to Know?

Chronic Idiopathic Urticaria

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Checkpoint Inhibition

Checkpoint Inhibition

Multidisciplinary Perspectives on Interstitial Lung Diseases

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Management of CMV in HSCT Recipients

Evaluating Next-Generation BTK Inhibitors

Gene Therapy: Past, Present, and Future

Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Skin.

Emerging Atopic Dermatitis Treatments:

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Immunotherapy for cSCC

Novel Approaches in T1D Management

Updates in Neurogenic Orthostatic Hypotension

New Recommendations on How to Stage Hidradenitis Suppurativa

When Is Biologic Therapy Appropriate for HS?

Improving Outcomes in Psoriatic Arthritis

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Parkinson Disease Psychosis

Immune Checkpoint Inhibitors in Lung Cancer

Guide to Atopic Dermatitis

Patient Questions and Expert Answers in Psoriasis:

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

Evaluating BTK Inhibitors in CLL

Optimizing Joint Health in Hemophilia

Possible Causes of imAEs

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

How to Select Therapy in Relapsed/Refractory CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

The Nurse View.

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.

Presentation transcript:

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Liver

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Checkpoint Inhibitors

General Risk for imAEs

The Liver

Upper Limit of Normal

Liver Function Tests

Hepatitis

What to Exclude When Diagnosing Immune-Mediated Hepatitis

Biopsy

Hepatitis Grades

Management of Grade 1-2 Hepatitis

Management of Grade 3-4 Hepatitis

Observational Study of Patients Who Developed Immune-Mediated Hepatitis

Consulting the Gastroenterologist/ Hepatologist

Steroid-Refractory Patients

General Safety of Retreatment

Restarting Therapy in Patients With Hepatitis

PD-1 Inhibitors in Patients With HCC

Concluding Remarks

Abbreviations